# A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours

> **NCT03990233** · PHASE1 · COMPLETED · sponsor: **OSE Immunotherapeutics** · enrollment: 100 (actual)

## Conditions studied

- Solid Tumor, Adult

## Interventions

- **DRUG:** BI 765063
- **DRUG:** BI 754091

## Key facts

- **NCT ID:** NCT03990233
- **Lead sponsor:** OSE Immunotherapeutics
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2019-04-16
- **Primary completion:** 2023-04-17
- **Final completion:** 2025-04-30
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2025-06-26

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03990233

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03990233, "A Trial of BI 765063 Monotherapy and in Combination With BI 754091 in Patients With Advanced Solid Tumours". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03990233. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*